Small and Rural
CMS releases FY 2018 inpatient PPS final rule
The Centers for Medicare & Medicaid Services yesterday issued final fiscal year 2018 rules for the hospital inpatient prospective payment system and long-term care hospital PPS.
The Centers for Medicare & Medicaid Services (CMS) August 2 issued its hospital inpatient prospective payment system (PPS) and long-term care hospital (LTCH) PPS final rule for fiscal year (FY) 2018. Select highlights of the final rule related to the inpatient PPS follow.
The Centers for Medicare & Medicaid Services late today issued its hospital inpatient prospective payment system final rule for fiscal year 2018. The rule will increase rates by 1.2% in FY 2018, after accounting for inflation and other adjustments required by law.
Senators early this morning voted 49-51 against a skinny bill to repeal parts of the Affordable Care Act.
The Centers for Medicare & Medicaid Services today issued a proposed rule that delineates a methodology for implementing the Affordable Care Act aggregate reductions to state Medicaid Disproportionate Share Hospital allotments beginning in fiscal year 2018. The ACA reduces state Medicaid DSH…
CMS today issued a proposed rule that would implement the Affordable Care Act requirement for aggregate reductions to be made to state Medicaid Disproportionate Share Hospital (DSH) allotments for fiscal year (FY) 2018. Highlights of the proposed rule follow.
Senate Republican leaders July 20 unveiled a revised version of the Better Care Reconciliation Act of 2017, legislation to repeal and replace parts of the Affordable Care Act.
The Health Resources and Services Administration today recognized 10 states whose critical access hospitals had the highest quality reporting rates and performance improvement under the Medicare Beneficiary Quality Improvement Project during the past year: Wisconsin, Maine, Utah, Minnesota,…
Senate leadership today released the Obamacare Repeal Reconciliation Act of 2017 (H.R. 1628).
The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders.